Initial $5.6M senior secured convertible notes and warrants closed July 6, with up to $5.6M additional funding tied to commercial milestones. Milestones include a 150% boost in ReWalk unit sales over 12 months or shares trading at $13.80 or higher for ten days.
Lifeward closed an initial $5.6 million financing round on July 6 by issuing senior secured convertible notes and accompanying warrants to a group of institutional and accredited investors.
Investors are committed to purchase an additional $5.6 million of notes and warrants upon achieving either a 150% increase in ReWalk unit sales over the trailing twelve months or Lifeward shares trading at or above $13.80 per share for ten consecutive trading days.
This financing builds on an existing strategic framework providing access to up to $47 million, including $10 million already funded, and will accelerate commercial deployment of Lifeward’s restorative healthcare platform while expanding its reimbursement-backed distribution model and advancing its product portfolio.
